WELCOME TO UPSTATE SC AND NORTHEAST GEORGIA'S #1 STATION FOR TODAY'S R&B AND OLD SCHOOL.......FOR YOUR ADVERTISING NEEDS BECOME A BUSINESS PARTNER TODAY!

Elite Glass and Mirror
My Econ Web Banner
Anderson Chamber

Listen live

If the Player does not start after 5 seconds click here to download the plugin.

ARTICLE

First Blood Test to Help Diagnose Alzheimer’s Goes On Sale
POSTED BY WLAS December 1st, 2020 0 COMMENTS

A company has started selling the first blood test to help diagnose Alzheimer’s disease, a leap for the field that could make it much easier for people to learn whether they have dementia. It also raises concern about the accuracy and impact of such life-altering news.

Independent experts are leery because key test results have not been published and the test has not been approved by the U.S. Food and Drug Administration — it’s being sold under more general rules for commercial labs. But they agree that a simple test that can be done in a doctor’s office has long been needed.

It might have spared Tammy Maida a decade of futile trips to doctors who chalked up her symptoms to depression, anxiety or menopause before a $5,000 brain scan last year finally showed she had Alzheimer’s.

“I now have an answer,” said the 63-year-old former nurse from San Jose, California.

If a blood test had been available, “I might have been afraid of the results” but would have “jumped on that” to find out, she said.

More than 5 million people in the United States and millions more around the world have Alzheimer’s, the most common form of dementia. To be diagnosed with it, people must have symptoms such as memory loss plus evidence of a buildup of a protein called beta-amyloid in the brain.

The best way now to measure the protein is a costly PET brain scan that usually is not covered by insurance. That means most people don’t get one and are left wondering if their problems are due to normal aging, Alzheimer’s or something else.

The blood test from C2N Diagnostics of St. Louis aims to fill that gap. The company’s founders include Drs. David Holtzman and Randall Bateman of Washington University School of Medicine, who headed research that led to the test and are included on a patent that the St. Louis university licensed to C2N.

ABOUT THE TEST

The test is not intended for general screening or for people without symptoms — it’s aimed at people 60 and older who are having thinking problems and are being evaluated for Alzheimer’s. It’s not covered by insurance or Medicare; the company charges $1,250 and offers discounts based on income. Only doctors can order the test and results come within 10 days. It’s sold in all but a few states in the U.S. and just was cleared for sale in Europe.

It measures two types of amyloid particles plus various forms of a protein that reveal whether someone has a gene that raises risk for the disease. These factors are combined in a formula that includes age, and patients are given a score suggesting low, medium or high likelihood of having amyloid buildup in the brain.

If the test puts them in the low category, “it’s a strong reason to look for other things” besides Alzheimer’s, Bateman said.

“There are a thousand things that can cause someone to be cognitively impaired,” from vitamin deficiencies to medications, Holtzman said.

“I don’t think this is any different than the testing we do now” except it’s from a blood test rather than a brain scan, he said. “And those are not 100% accurate either.”

LIKE BLACKAMERICAWEB ON FACEBOOK. FOLLOW US ON INSTAGRAM & TWITTER.

Comments are closed.

Click to tour ship

Cococay Cozumel Cruise

Recommend us


Business of the Week

    Business Name (required)

    Address

    Telephone (required)

    Website

    Contact Person (required)

    Log In

    business partners

    Kia of Anderson
    A and D Auto Sales
    S and M Auto Parts
    A-1 Auto Sales
    Marine Corps
    Heat trophy
    Dr Anthony Mathis
    Welborn Tire Pros